| Interaction landscape of inherited polymorphisms with somatic events in cancer H Carter, R Marty, M Hofree, AM Gross, J Jensen, KM Fisch, X Wu, ... Cancer discovery 7 (4), 410-423, 2017 | 143 | 2017 |
| Inhibition of mTOR signaling and clinical activity of rapamycin in head and neck cancer in a window of opportunity trial TA Day, K Shirai, PE O'Brien, MG Matheus, K Godwin, AJ Sood, ... Clinical Cancer Research 25 (4), 1156-1164, 2019 | 81 | 2019 |
| 4E-BP1 is a tumor suppressor protein reactivated by mTOR inhibition in head and neck cancer Z Wang, X Feng, AA Molinolo, D Martin, L Vitale-Cross, N Nohata, M Ando, ... Cancer research 79 (7), 1438-1450, 2019 | 63 | 2019 |
| Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma JS Paradis, M Acosta, R Saddawi-Konefka, A Kishore, S Lubrano, ... Clinical Cancer Research 27 (11), 3190-3200, 2021 | 47 | 2021 |
| Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions JS Gutkind, AA Molinolo, X Wu, Z Wang, D Nachmanson, O Harismendy, ... JCI insight 6 (17), 2021 | 39 | 2021 |
| Metformin inhibits progression of head and neck squamous cell carcinoma by acting directly on carcinoma-initiating cells X Wu, H Yeerna, Y Goto, T Ando, VH Wu, X Zhang, Z Wang, ... Cancer research 79 (17), 4360-4370, 2019 | 36 | 2019 |
| AFF4 promotes tumorigenesis and tumor-initiation capacity of head and neck squamous cell carcinoma cells by regulating SOX2 P Deng, J Wang, X Zhang, X Wu, N Ji, J Li, M Zhou, L Jiang, X Zeng, ... Carcinogenesis 39 (7), 937-947, 2018 | 30 | 2018 |
| Interaction landscape of inherited polymorphisms with somatic events in cancer. Cancer Discov. 2017; 7: 410–423. doi: 10.1158/2159-8290 H Carter, R Marty, M Hofree, AM Gross, J Jensen, KM Fisch, X Wu, ... CD-16-1045.[PMC free article][PubMed][Cross Ref], 0 | 26 | |
| Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer H Izumi, Z Wang, Y Goto, T Ando, X Wu, X Zhang, H Li, DE Johnson, ... Molecular cancer therapeutics 19 (7), 1562-1571, 2020 | 23 | 2020 |
| KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort X Jin, H Xu, X Wu, T Li, J Li, Y Zhou, H Dan, L Jiang, X Zeng, P Ji, Q Chen Oncotarget 8 (46), 80348, 2017 | 10 | 2017 |
| Identifying novel molecular vulnerabilities to PTK2/FAK inhibition in G α q‐driven uveal melanoma using a kinome‐wide CRISPR/Cas9 screen A Kishore, X Feng, N Arang, X Wu, J Pachter, DD Schlaepfer, P Tamayo, ... The FASEB Journal 33 (S1), 647.15-647.15, 2019 | 1 | 2019 |
| Gαs is dispensable for β-arrestin coupling but dictates GRK selectivity and is predominant for gene expression regulation by β2-adrenergic receptor V Burghi, JS Paradis, A Officer, SR Adame-Garcia, X Wu, ESF Matthees, ... Journal of Biological Chemistry 299 (11), 2023 | | 2023 |
| A kinome-wide synthetic lethal CRISPR/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4/CDK6 blockade in HNSCC Y Goto, K Koshizuka, T Ando, H Izumi, X Wu, K Ford, X Feng, Z Wang, ... bioRxiv, 2023.08. 07.552216, 2023 | | 2023 |
J. Silvio Gutkind, Ph.D.UCSD, Distinguished Professor and Chair, Dept. Pharmacology, AD Basic Science Moores Cancer CenterVerified email at ucsd.edu
